Daily pill may be as
effective as Ozempic
A new GLP-1 drug may be as effective as Ozempic and Mounjaro for weight loss and blood sugar control with just a daily pill. The New York Times reports that orforglipron from drugmaker Eli Lilly produced similar results in clinical trials as injectable GLP-1 drugs, which must be carefully transported and refrigerated until use. Lilly plans to seek approval later this year and the new drug is expected to hit the market in 2026.
Step count may be the key to reducing cancer risk
Intense workouts may not be necessary to reap the cancer-preventing benefits of exercise. According to a new study published in the British Journal of Sports Medicine, even light physical activity like walking is associated with significantly decreased risk for certain types of cancer. Study participants who averaged 7,000 steps per day (regardless of intensity) were 11 percent less likely to develop cancer, while those who clocked in at 9,000 were 16 percent less likely.
Marijuana use linked with dementia
People who require emergency care or hospitalization related to marijuana use are substantially more likely to develop dementia than other patients, according to a new study published in the journal JAMA Neurology. Researchers examined medical records for more than 6 million Ontario residents and found that people who sought care for cannabis-related reasons were 23 percent more likely to develop dementia within five years compared to other patients during the same period, and 72 percent more likely to develop dementia at any point. Regular cannabis users are also nearly 25 percent more likely to require emergency care and hospitalization.